Corcept Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Corcept Therapeutics şirketinin toplam hissedar öz sermayesi $638.8M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $784.3M ve $145.4M dir. Corcept Therapeutics 'in FAVÖK'ü $143.4M faiz karşılama oranı -6.2 dur. Şirketin $380.3M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	-6.2x
Nakit	US$380.34m
Eşitlik	US$638.84m
Toplam yükümlülükler	US$145.42m
Toplam varlıklar	US$784.26m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Sep 28

If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Sep 06

Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

Aug 01

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

Apr 15

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Dec 23

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Nov 07

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Jun 23

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Feb 16

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Jan 11

Corcept Therapeutics starts phase 2 trial of its ALS treatment

Oct 11

Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Sep 27

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CORT 'nin kısa vadeli varlıkları ( $467.0M ) kısa vadeli yükümlülüklerini ( $126.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: CORT şirketinin kısa vadeli varlıkları ( $467.0M ) uzun vadeli yükümlülüklerini ( $19.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CORT borçsuzdur.

Borcun Azaltılması: CORT un 5 yıl önce borcu yoktu.

Borç Kapsamı: CORT un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: CORT şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Corcept Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 21%

Chief Development Officer notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Increases Earnings Guidance for the Year 2024

Corcept Therapeutics Incorporated to Report Q3, 2024 Results on Oct 30, 2024

Price target increased by 14% to US$74.64

Chief Business Officer & Secretary notifies of intention to sell stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Investor sentiment improves as stock rises 19%

If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Chief Development Officer notifies of intention to sell stock

Consensus EPS estimates increase by 20%

Co-Founder exercised options and sold US$9.2m worth of stock

Price target increased by 20% to US$59.60

Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated to Report Q2, 2024 Results on Jul 29, 2024

Chief Business Officer & Secretary notifies of intention to sell stock

Price target increased by 14% to US$49.70

Chief Development Officer notifies of intention to sell stock

Corcept Announces Primary Endpoint Met in Pivotal Phase 3 Grace Trial of Relacorilant in Patients with Hypercortisolism (Cushing’S Syndrome)

President of Endocrinology notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Completes Enrollment in Phase 4 Catalyst Trial

Corcept Therapeutics Incorporated to Report Q1, 2024 Results on May 01, 2024

Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

New minor risk - Shareholder dilution

Corcept Therapeutics Incorporated, Annual General Meeting, May 17, 2024

Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

Chief Accounting Officer notifies of intention to sell stock

Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome

President of Endocrinology notifies of intention to sell stock

President of Endocrinology exercised options and sold US$364k worth of stock

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

President of Endocrinology notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Announces Preliminary Results from Prevalence Phase of CATALYST Clinical Trial

Corcept Therapeutics Incorporated to Report Q4, 2023 Results on Feb 15, 2024

Price target increased by 11% to US$39.60

New minor risk - Share price stability

Corcept Therapeutics Incorporated Appoints Roberto Vieira as President, Oncology

Chief Scientific Officer exercised options and sold US$728k worth of stock

Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024

Chief Development Officer notifies of intention to sell stock

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

President of Corcept Endocrinology notifies of intention to sell stock

Consensus EPS estimates increase by 13%

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Price target increased by 8.1% to US$36.83

President of Corcept Endocrinology notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Appoints Monica Tellado as President, Emerging Markets

Corcept Therapeutics Incorporated Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis

Corcept Therapeutics Incorporated to Report Q3, 2023 Results on Nov 01, 2023

President of Corcept Endocrinology exercised options and sold US$452k worth of stock

President of Corcept Endocrinology notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

President of Corcept Endocrinology notifies of intention to sell stock

Chief Scientific Officer recently sold US$632k worth of stock

Chief Scientific Officer exercised options and sold US$811k worth of stock

Investor sentiment improves as stock rises 22%

Price target increased by 7.3% to US$32.92

Corcept Therapeutics Incorporated to Report Q2, 2023 Results on Aug 02, 2023

Corcept Therapeutics Incorporated Publishes Results of Corcept’S Phase 2 Trial of Relacorilant in Women with Platinum-Resistant Ovarian Cancer

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Chief Accounting Officer notifies of intention to sell stock

Chief Business Officer & Secretary recently sold US$1.1m worth of stock

Chief Business Officer & Secretary exercised options and sold US$1.3m worth of stock

Consensus EPS estimates fall by 21%, revenue upgraded

First quarter 2023 earnings: EPS misses analyst expectations

Corcept Therapeutics Incorporated Revises Revenue Guidance for 2023

Insufficient new directors